Ginkgo Bioworks Holdings, Inc. (DNA)
6.80
+0.40
(+6.25%)
USD |
NYSE |
Mar 13, 16:00
6.82
+0.02
(+0.29%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 421.09M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 5.26% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 2.200 |
| Price to Book Value | 0.8279 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.8649 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA. |
| URL | http://www.ginkgo.bio |
| Investor Relations URL | https://investors.ginkgobioworks.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | May. 05, 2026 (est.) |
| Last Earnings Release | Feb. 26, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA. |
| URL | http://www.ginkgo.bio |
| Investor Relations URL | https://investors.ginkgobioworks.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | May. 05, 2026 (est.) |
| Last Earnings Release | Feb. 26, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |